0001689375-24-000007.txt : 20240308 0001689375-24-000007.hdr.sgml : 20240308 20240308163426 ACCESSION NUMBER: 0001689375-24-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240306 FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dowden Nathan J CENTRAL INDEX KEY: 0001873392 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40969 FILM NUMBER: 24734983 MAIL ADDRESS: STREET 1: 6 TIDE STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entrada Therapeutics, Inc. CENTRAL INDEX KEY: 0001689375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813983399 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE DESIGN CENTER PLACE STREET 2: SUITE 17-500 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-305-1825 MAIL ADDRESS: STREET 1: ONE DESIGN CENTER PLACE STREET 2: SUITE 17-500 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: CycloPorters, Inc. DATE OF NAME CHANGE: 20161104 4 1 wk-form4_1709933649.xml FORM 4 X0508 4 2024-03-06 0 0001689375 Entrada Therapeutics, Inc. TRDA 0001873392 Dowden Nathan J C/O ENTRADA THERAPEUTICS, INC. ONE DESIGN CENTER PLACE, SUITE 17-500 BOSTON MA 02210 0 1 0 0 President & COO 1 Common Stock 2024-03-06 4 S 0 1826 12.3213 D 137204 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.02 to $12.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Jared Cohen, as Attorney-in-Fact 2024-03-08